Wells Fargo’s Processa Pharmaceuticals PCSA Stock Holding History

Wells Fargo’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6	Closed	-$15	–	7522
2026 Q1	$15	Hold	6	–	–	﹤0.01%	6864
2025 Q4	$17	Hold	6	–	–	﹤0.01%	6773
2025 Q3	$30	Hold	6	–	–	﹤0.01%	6605
2025 Q2	$32	Hold	6	–	–	﹤0.01%	6668
2025 Q1	$57	Hold	6	–	–	﹤0.01%	6436
2024 Q4	$136	Hold	6	–	–	﹤0.01%	6393
2024 Q3	$211	Hold	6	–	–	﹤0.01%	6225
2024 Q2	$345	Sell	6 -1	-14%	-$49	﹤0.01%	6171
2024 Q1	$402	Buy	7 +1	+17%	+$79	﹤0.01%	6328
2023 Q4	$1.09K	Hold	6	–	–	﹤0.01%	6204
2023 Q3	$810	Hold	6	–	–	﹤0.01%	6247
2023 Q2	$1.6K	Hold	6	–	–	﹤0.01%	6249
2023 Q1	$1.58K	Hold	6	–	–	﹤0.01%	6267
2022 Q4	$3.47K	Hold	6	–	–	﹤0.01%	5868
2022 Q3	$7K	Hold	6	–	–	﹤0.01%	5818
2022 Q2	$9K	Hold	6	–	–	﹤0.01%	5800
2022 Q1	$9K	Buy	+6	New	+$11.4K	﹤0.01%	6311
2021 Q4	–	Hold	0	–	–	–	7654
2021 Q3	–	Hold	0	–	–	–	6764
2021 Q2	–	Hold	0	–	–	–	7294
2021 Q1	–	Hold	0	–	–	–	7245
2020 Q4	–	Hold	0	–	–	–	6863

Other funds holding PCSA

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo's PCSA Position: Q2 2026 in Review

Wells Fargo sold out of Processa Pharmaceuticals (PCSA) in Q2 2026, closing a stake of 6 shares — an estimated $15 sold.

Wells Fargo first reported a position in PCSA in Q1 2022 and held it in 17 quarters. The position peaked at $9K in Q2 2022. 11 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

Wells Fargo reported no remaining Processa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Wells Fargo sold 6 Processa Pharmaceuticals shares in Q2 2026, an estimated $15.
Wells Fargo first reported a position in Processa Pharmaceuticals in Q1 2022 and held it in 17 quarters.
Wells Fargo's Processa Pharmaceuticals position peaked at $9K in Q2 2022.
11 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.